TheThe 16th International Society of Paediatric Oncology (SIOP) Asia Annual Conference (SIOP Asia) was held in Yokohama, Japan, from June 22 to 25 this year. It was hosted by Japan's National Center for Child Health and Development and organized in collaboration with the Japanese Society of Pediatric Hematology/Oncology (JSPHO), the Japan Children's Cancer Group (JCCG), the Japanese Childhood Cancer Association, and the NPO Magokoro Childhood Cancer Organization.Dr. Yu Lei, Chairman of UNICAR-THERAPY, was invited to attend2024 SIOP Asia Annual Meeting, shared at the conferenceCell TherapyThe development of technology and Unicar-Therapy inBreakthroughs and Innovations in CAR-T Technology.
Dr. Lei Yu, Chairman of UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTDIn2024 SIOP AsiaAnnual Report
Famous American BiologistGeorge Daley once predicted:“The 20th century was the era of drug therapy, and the 21st century will be the era of cell therapy.”. In terms of dimensions, and chemical drugs, radiotherapy, physical therapy, etc.Compared with traditional treatment methods, cell therapy is“Dimensionality Reduction Therapy”Mode。Cell therapy, as one of the most prominent biotechnology fields in recent years, has gradually matured and entered a rapid development phase. As a revolutionary treatment, immune cell therapy has achieved remarkable progress in multiple difficult-to-treat diseases such as cancer and autoimmune disorders, particularly in patients with relapsed or refractory hematological malignancies.CAR-T is the fastest progressing field of immunotherapy in clinical trials globally.，The Number of Clinical Trials Continues to Grow，From the United StatesSince the FDA's first approval of CD19-targeted CAR-T cell therapy,As of now, globally there are a total of11 CAR-T Cell Therapy Products Approved for Marketing. CAR-T drugs are the only hope for survival for patients with advanced blood tumors such as leukemia, lymphoma, and multiple myeloma at this stage, andHave gradually begun to cover patients who failed in first-line treatment., with huge market potential.UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTD asCAR-T Cell Therapy InnovationField ofLeader, adhering to independent innovation, has solved many"Chokepoint" issues, breaking through the "me too" comfort zone, SHANGHAI UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTD successfully developed multiple technologically iterative CAR-T products, completing a four-stage layout in technology: from autologous CAR-T, to CAR-T cell empowerment, to universal CAR technology, and finally to in vivo CAR formation. The world's first safe fourth-generation CAR-T product, ssCART-19 Injection, precisely addresses the safety concerns of CAR-T in leukemia treatment. It can be groundbreaking for treating central nervous system leukemia (commonly known as "brain leukemia"), a contraindication for traditional CAR-T therapy. In 2022, it received orphan drug designation from the U.S. FDA and was included in China’s list of breakthrough therapies in 2024. Multiple iterative CAR-T products developed by UNICAR-THERAPY for hematological malignancies and solid tumors have demonstrated excellent clinical outcomes. Notably, the first Chinese patient with advanced acute lymphoblastic leukemia treated has been cancer-free for nearly nine years, fully showcasing the effectiveness of UNICAR-THERAPY's products.SelfSince its establishment in 2015, SHANGHAI UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTD has collaborated with multiple well-known clinical institutions both domestically and internationally, completing thousands of clinical studies. Its innovative capabilities have been widely recognized by clinical institutions worldwide. Currently, it has partnered with the world's leading children's hospital-National Center for Child Health and Development, JapanAchieve in-depth cooperation, which will provide authoritative global medical resources and safe and effective products for children with leukemia, improve patient prognosis, and bring new hope to cancer patients.
About UNICAR-THERAPY
SHANGHAI UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTD (hereinafter referred to as"UNICAR-THERAPY" was established in February 2015 at the Zhangjiang Bio-High Tech Incubation Center in Shanghai, China.，It is a biopharmaceutical company dedicated to the innovation and transformation of global cell therapy technology, with multiple productsfirst-in-class/first-in-safeThe product is in the clinical trial stage.UNICAR-THERAPY has multiple original core technology platforms, includingSMART Small Nucleotide Gene Regulation Empowerment Technology Platform, MADDS Antibody Innovation Drugability Technology Platform, 6H Production Quality Control Platform, etc. Moreover, the company has established a closed CAR-T production system in Baoshan, with a construction area of approximately 10,000 square meters, to build an internationally advanced billion-level gene and cell therapy research, industrialization, and commercialization center. This will create a world-class immunotherapy tumor innovation technology transformation center and an advanced, high-end genetically engineered immune cell industry chain center, mainly including the industrial production of CAR-T products and CDMO services for plasmids, viruses, and CAR-T cells.UNICAR-THERAPY has a wide range of product pipelines, including products for the treatment of hematological tumors, solid tumors, and autoimmune diseases. The companyInnovative ProductsssCART-19 InjectionCanBreakthrough UseThe treatment of CAR-T contraindications for central nervous system leukemia (commonly known as "CNSL") has now entered a critical clinical stage. SHANGHAI UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTDMultipleCollaboration with well-known clinical institutions at home and abroad successfully treatedThousandsExample of Advanced Cancer Patients。
